CLINICAL TRIALS PROFILE FOR MYCAMINE
✉ Email this page to a colleague
All Clinical Trials for Mycamine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00047827 ↗ | Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis | Terminated | Astellas Pharma Inc | Phase 2 | 2002-12-01 | The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis. |
| NCT00048750 ↗ | Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU | Terminated | Astellas Pharma Inc | Phase 3 | 2003-01-01 | The purpose of this study is to determine the efficacy and safety of intravenous micafungin versus placebo as prophylactic therapy for invasive fungal infections in patients in the intensive care unit considered to be at high risk. |
| NCT00105144 ↗ | Study of Micafungin in Patients With Invasive Candidiasis or Candidemia | Completed | Astellas Pharma Inc | Phase 3 | 2004-09-01 | The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia. |
| NCT00106288 ↗ | Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia | Completed | Astellas Pharma Inc | Phase 3 | 2003-01-01 | The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and pediatric patients. |
| NCT00423163 ↗ | A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis | Withdrawn | Astellas Pharma Inc | Phase 4 | 2007-02-01 | To evaluate the therapeutic effectiveness of voriconazole + micafungin versus voriconazole alone as primary therapy for invasive aspergillosis. |
| NCT00607763 ↗ | Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug | Completed | Astellas Pharma Inc | Phase 1 | 2007-10-01 | Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an antifungal drug. Safety and drug blood levels will be assessed |
| NCT00608335 ↗ | Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug | Completed | Astellas Pharma Inc | Phase 1 | 2007-10-14 | Children with fungal infections will be divided into two groups by weight. Children weighing < 25 kg will receive a higher dose of study medication (per kg body weight) for 10 to 14 days than children weighing > 25 kg. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Mycamine
Condition Name
Clinical Trial Locations for Mycamine
Trials by Country
Clinical Trial Progress for Mycamine
Clinical Trial Phase
Clinical Trial Sponsors for Mycamine
Sponsor Name
